Carl Zeiss Meditec (ETR:AFX) PT Set at €90.00 by Independent Research

Share on StockTwits

Carl Zeiss Meditec (ETR:AFX) received a €90.00 ($104.65) target price from stock analysts at Independent Research in a research note issued on Friday, Borsen Zeitung reports. The firm presently has a “sell” rating on the stock. Independent Research’s target price would suggest a potential downside of 12.45% from the stock’s current price.

Several other research analysts have also recently weighed in on AFX. Berenberg Bank set a €93.00 ($108.14) target price on Carl Zeiss Meditec and gave the stock a “neutral” rating in a report on Wednesday, July 17th. Nord/LB set a €98.00 ($113.95) price objective on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Wednesday. HSBC set a €98.00 ($113.95) price objective on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Wednesday, August 14th. Finally, Deutsche Bank set a €89.00 ($103.49) price objective on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Monday, August 12th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of €85.06 ($98.91).

Shares of Carl Zeiss Meditec stock opened at €102.80 ($119.53) on Friday. The stock has a market cap of $9.19 billion and a P/E ratio of 60.05. The stock’s 50 day simple moving average is €95.80 and its 200-day simple moving average is €85.50. Carl Zeiss Meditec has a 1-year low of €60.25 ($70.06) and a 1-year high of €104.30 ($121.28). The company has a debt-to-equity ratio of 4.55, a current ratio of 4.11 and a quick ratio of 3.09.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.

See Also: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Carl Zeiss Meditec (ETR:AFX)

Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Citadel Advisors LLC Makes New Investment in SPDR Portfolio Long Term Corporate Bond ETF
Citadel Advisors LLC Makes New Investment in SPDR Portfolio Long Term Corporate Bond ETF
Citadel Advisors LLC Has $21.24 Million Position in Cable One Inc
Citadel Advisors LLC Has $21.24 Million Position in Cable One Inc
Citadel Advisors LLC Raises Stock Holdings in SITE Centers Corp.
Citadel Advisors LLC Raises Stock Holdings in SITE Centers Corp.
Citadel Advisors LLC Sells 172,873 Shares of Telephone & Data Systems, Inc.
Citadel Advisors LLC Sells 172,873 Shares of Telephone & Data Systems, Inc.
Citadel Advisors LLC Sells 1,224,750 Shares of Hudbay Minerals Inc
Citadel Advisors LLC Sells 1,224,750 Shares of Hudbay Minerals Inc
Citadel Advisors LLC Acquires 4,838 Shares of First Interstate Bancsystem Inc
Citadel Advisors LLC Acquires 4,838 Shares of First Interstate Bancsystem Inc


© 2006-2019 Ticker Report